4th Quarter - Report

TIBER CREEK GROUP for JAZZ PHARMACEUTICALS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the FDA and S. 3032 - the FDA STATES Act (115th Congress), and Health and Human Services pertaining to CBD policies.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
MATTHEW LEFFINGWELL —
TIMOTHY A MOLINO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3032 (117th)

Medical/Disease Research/Clinical Labs MED

Issues related to cannabis research; S. 253 Cannabidiol and Marihuana Research Expansion Act; issues related to the FDA; issues related to Cannabis research at Health and Human Services.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
MATTHEW LEFFINGWELL —
TIMOTHY A MOLINO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 253 (117th)

Budget/Appropriations BUD

Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Consolidated Appropriations Act, 2023 (PL 117-328).

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
MATTHEW LEFFINGWELL —
TIMOTHY A MOLINO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.